Leerink Partnrs Brokers Increase Earnings Estimates for CNTA

Centessa Pharmaceuticals plc (NASDAQ:CNTA) – Stock analysts at Leerink Partnrs upped their Q2 2025 earnings estimates for shares of Centessa Pharmaceuticals in a note issued to investors on Wednesday, May 14th. Leerink Partnrs analyst D. Risinger now anticipates that the company will post earnings of ($0.35) per share for the quarter, up from their prior forecast of ($0.38). The consensus estimate for Centessa Pharmaceuticals’ current full-year earnings is ($1.60) per share. Leerink Partnrs also issued estimates for Centessa Pharmaceuticals’ Q3 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.34) EPS, FY2026 earnings at ($1.57) EPS, FY2027 earnings at ($1.64) EPS, FY2028 earnings at ($1.83) EPS and FY2029 earnings at $0.82 EPS.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.15.

Several other brokerages also recently commented on CNTA. Chardan Capital assumed coverage on Centessa Pharmaceuticals in a report on Thursday, May 8th. They set a “buy” rating and a $30.00 target price for the company. Piper Sandler initiated coverage on shares of Centessa Pharmaceuticals in a research note on Monday, March 31st. They set an “overweight” rating and a $38.00 price objective for the company. Morgan Stanley reiterated an “overweight” rating and issued a $27.00 target price on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Guggenheim reissued a “buy” rating and issued a $28.00 target price on shares of Centessa Pharmaceuticals in a research report on Wednesday, March 26th. Finally, Oppenheimer started coverage on shares of Centessa Pharmaceuticals in a research report on Thursday, May 8th. They issued an “outperform” rating and a $6.00 price target for the company. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $27.00.

Centessa Pharmaceuticals Stock Performance

CNTA opened at $13.20 on Monday. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The firm has a market cap of $1.76 billion, a PE ratio of -8.63 and a beta of 1.53. The business has a fifty day simple moving average of $13.31 and a 200-day simple moving average of $15.54. Centessa Pharmaceuticals has a fifty-two week low of $7.75 and a fifty-two week high of $19.09.

Insider Buying and Selling

In related news, insider David M. Chao sold 7,000 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $17.17, for a total value of $120,190.00. Following the completion of the sale, the insider now owns 225,007 shares of the company’s stock, valued at approximately $3,863,370.19. The trade was a 3.02% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Saurabh Saha sold 55,000 shares of the stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $15.93, for a total value of $876,150.00. Following the completion of the transaction, the chief executive officer now owns 331,017 shares in the company, valued at $5,273,100.81. This represents a 14.25% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 220,398 shares of company stock worth $3,299,392. 7.09% of the stock is owned by company insiders.

Institutional Trading of Centessa Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in CNTA. Jane Street Group LLC acquired a new position in shares of Centessa Pharmaceuticals during the 1st quarter worth $2,176,000. Exome Asset Management LLC boosted its holdings in Centessa Pharmaceuticals by 3.7% in the first quarter. Exome Asset Management LLC now owns 142,744 shares of the company’s stock worth $2,053,000 after purchasing an additional 5,028 shares in the last quarter. Millennium Management LLC increased its position in Centessa Pharmaceuticals by 52.9% during the first quarter. Millennium Management LLC now owns 609,188 shares of the company’s stock worth $8,760,000 after buying an additional 210,737 shares during the last quarter. Cutter Capital Management LP raised its holdings in Centessa Pharmaceuticals by 184.3% during the first quarter. Cutter Capital Management LP now owns 418,127 shares of the company’s stock valued at $6,013,000 after buying an additional 271,051 shares in the last quarter. Finally, Allostery Investments LP lifted its position in shares of Centessa Pharmaceuticals by 34.4% in the first quarter. Allostery Investments LP now owns 382,524 shares of the company’s stock worth $5,501,000 after buying an additional 98,007 shares during the last quarter. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.